NCT00654979CompletedNot Applicable
A Pivotal Study to Evaluate the Safety and Effectiveness of RMT Medical Technology's SafeFlo® Vena Cava Filter
RMT Medical Technologies, Ltd.8 sites in 6 countries117 target enrollmentStarted: July 1, 2003Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 117
- Locations
- 8
- Primary Endpoint
- Clinical success will be defined as no occurrences of any of the following events: recurrent pulmonary embolism, IVC occlusion or filter embolization.
Study Overview
Brief Summary
To determine the safety and effectiveness of the SafeFlo filter for permanent protection against pulmonary emboli. All patients will be selected to receive the filter according to the stated inclusion / exclusion criteria after consultation between the attending physician and interventional radiologist. Patients with a permanent implantation will be followed for up to 6 months. Clinical success will be defined as no occurrences of any of the following events: recurrent pulmonary embolism, IVC occlusion or filter embolization. The proportion of permanent filter patients considered to be a clinical success will be the primary efficacy parameter.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Prevention
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Traditional indications for vena cava filter in patients with established DVT or PE, including (40):
- •Patients with proven Pulmonary Embolus (PE) or Deep Vein Thrombosis (DVT) and one or more of the following:
- •Contraindication to anticoagulation
- •Complication of anticoagulation
- •Failure of anticoagulation
- •Recurrent PE despite adequate anticoagulation therapy
- •Inability to achieve adequate anticoagulation
- •Poor compliance with anticoagulation medications
- •Extended indications for vena cava filter placement in patients with established DVT or PE, including the following (31, 40):
- •Large free-floating thrombus in the iliac vein or IVC;
- •Following massive PE in which recurrent emboli may prove fatal;
- •During/after surgical or transcatheter embolectomy;
- •Filter placement in high-risk trauma and orthopedic patients:
- •High risk trauma or orthopedic patients who cannot receive anticoagulation because of increased bleeding risk, and have one or more of the following injury patterns (31, 40):
- •Severe closed head injury (GCS < 8);
- •Incomplete spinal cord injury with para or quadriplegia;
- •Complex pelvic fractures with associated long-bone fractures;
- •Multiple long bone fractures.
- •Patients undergoing long-term immobilization (e.g., ICU or Surgical oncology)
Exclusion Criteria
- •All patients under 18 years of age.
- •All patients undergoing emergency procedures.
- •All patients with abnormal IVC anatomy or pathology of the IVC such as thrombosis or tumor which prevent safe filter implantation.
- •All patients with an IVC diameter which precludes oversizing of the filter platform.
- •All patients with active infection / bacteremia.
- •All patients with sensitivity to contrast media.
- •Uncorrectable severe coagulopathy (e.g., patients with liver or multisystem failure).
Outcomes
Primary Outcomes
Clinical success will be defined as no occurrences of any of the following events: recurrent pulmonary embolism, IVC occlusion or filter embolization.
Time Frame: 6 months follow-up
Secondary Outcomes
- The proportion of patients with successful deployment of the filter will be calculated and presented with a 95% exact confidence interval.(3 and 6 months follow-up)
Investigators
Study Sites (8)
Loading locations...
Similar Trials
Unknown
Not Applicable
CLaret Embolic Protection ANd TAVI - TrialFrequency of Cerebral Perfusion Defects After TAVISize of Cerebral Perfusion Defects After TAVINCT01833052University of Leipzig100
Completed
Not Applicable
Post-Marketing Observational Study of Safety Following Vaccination With Flublok® Compared to Licensed IIV in AdultsHuman InfluenzaNCT02600585Protein Sciences Corporation254,648
Unknown
Phase 3
Protective Ventilatory Strategy in Potential Organ DonorsMechanical VentilationNCT00260676University of Turin, Italy200
Recruiting
Not Applicable
Safety and Efficacy of Prophylactic Re-sorbable Biosynthetic Mesh Following Midline Laparotomy in Clean/Contaminated Field.Incisional Hernia After Midline LaparotomyNCT04471311Azienda Sanitaria Locale Napoli 2 Nord151
Recruiting
Not Applicable
Prospective study to evaluate the protective effect of BellaCell acellular dermal matrix from radiation therapy in prosthetic breast reconstructioKCT0005935Asan Medical Center80